📊 VERU Key Takeaways
Is Veru Inc.. (VERU) a Good Investment?
VERU faces critical operational challenges evidenced by zero reported revenue despite operating as a pharmaceutical company, resulting in severe cash burn (-$15.1M operating cash flow) and unsustainable losses (-$12.6M operating income). While the company maintains a strong balance sheet with $27.6M in cash and minimal debt, this provides only 1.8-2 years of runway at current burn rates without demonstrated path to revenue generation.
Veru Inc.. Key Strengths (VERU)
- Exceptional balance sheet strength with 64% of assets in cash equivalents
- Minimal financial leverage (0.05x Debt/Equity ratio) with only $1.7M long-term debt
- Excellent liquidity position (6.19x current ratio) providing substantial operational cushion
- Net income improving 39.9% YoY suggests potential trajectory improvement from severe losses
VERU Stock Risks: Veru Inc.. Investment Risks
- Zero revenue reported is anomalous for pharmaceutical company, indicating major operational failure or data integrity issue
- Massive cash burn rate ($15.1M annually) depletes reserves rapidly without revenue offset
- Negative operating income (-$12.6M), ROE (-23.2%), and ROA (-18.7%) indicate fundamental unprofitability
- Limited financial runway of approximately 18-24 months at current burn rate before cash depletion
- Negative interest coverage (-40.7x) demonstrates inability to service debt from operations
- Zero capital expenditure suggests minimal investment in product development or growth initiatives
- Unexplained discrepancy between zero revenue and $5.9M gross profit raises data quality concerns
Key Metrics to Watch
- Revenue generation - critical indicator of whether company can resume commercial operations
- Operating cash flow trend - must turn positive to extend runway
- Cash burn rate and remaining runway - company has limited time before potential insolvency
- Product pipeline FDA approval status - determines future revenue potential
Veru Inc.. (VERU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.19x current ratio provides a solid financial cushion.
VERU Profit Margin, ROE & Profitability Analysis
VERU vs Healthcare Sector: How Veru Inc.. Compares
How Veru Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Veru Inc.. Stock Overvalued? VERU Valuation Analysis 2026
Based on fundamental analysis, Veru Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Veru Inc.. Balance Sheet: VERU Debt, Cash & Liquidity
VERU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Veru Inc..'s revenue has declined by 60% over the 5-year period, indicating business contraction. The most recent EPS of $-1.05 indicates the company is currently unprofitable.
VERU Revenue Growth, EPS Growth & YoY Performance
VERU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$7.3M | N/A |
| Q2 2025 | N/A | -$7.9M | N/A |
| Q3 2024 | $3.3M | -$8.3M | N/A |
| Q2 2024 | $4.1M | -$8.3M | $-0.07 |
| Q1 2024 | $2.1M | -$8.3M | $-0.08 |
| Q3 2023 | $3.3M | $6.3M | $0.07 |
| Q2 2023 | $6.6M | -$6.4M | $-0.18 |
| Q1 2023 | $2.5M | -$6.4M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Veru Inc.. Dividends, Buybacks & Capital Allocation
VERU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Veru Inc.. (CIK: 0000863894)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VERU
What is the AI rating for VERU?
Veru Inc.. (VERU) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VERU's key strengths?
Claude: Exceptional balance sheet strength with 64% of assets in cash equivalents. Minimal financial leverage (0.05x Debt/Equity ratio) with only $1.7M long-term debt.
What are the risks of investing in VERU?
Claude: Zero revenue reported is anomalous for pharmaceutical company, indicating major operational failure or data integrity issue. Massive cash burn rate ($15.1M annually) depletes reserves rapidly without revenue offset.
What is VERU's revenue and growth?
Veru Inc.. reported revenue of $0.0.
Does VERU pay dividends?
Veru Inc.. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find VERU SEC filings?
Official SEC filings for Veru Inc.. (CIK: 0000863894) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VERU's EPS?
Veru Inc.. has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VERU's fundamental grade?
Based on our AI fundamental analysis in June 2026, Veru Inc.. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VERU stock overvalued or undervalued?
Valuation metrics for VERU: ROE of -23.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VERU's AI grade for 2026?
Our dual AI analysis gives Veru Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VERU's free cash flow?
Veru Inc..'s operating cash flow is $-15.1M, with capital expenditures of $0.0.
How does VERU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -23.2% (avg: 15%), current ratio 6.19 (avg: 2).